Interface Laboratories

Infectious Disease Diagnostics IN DEVELOPMENT

Our diagnostic development program focuses on creating rapid, accurate assays for challenging pathogens, with C. difficile as our lead program. Currently in development with preliminary validation data, our assays aim to provide:

• Critical differentiation capability between colonization and active infection - addressing a major gap in current diagnostics
• Rapid turnaround times for critical treatment decisions
• High sensitivity and specificity for C. difficile detection
• Cost-effective implementation in clinical laboratories

Our diagnostic platform is designed to expand to other challenging pathogens as we validate our core technology. We're particularly focused on infections where current diagnostics fall short in distinguishing between harmless colonization and disease-causing infections - a critical clinical problem that leads to overtreatment, unnecessary antibiotic exposure, and increased antimicrobial resistance.

Antimicrobial Drug Discovery PRECLINICAL

Our drug discovery program targets neglected tropical diseases and resistant pathogens through structure-based drug design. With preclinical candidates in development, we focus on:

• Novel antifungal compounds targeting resistant Candida and Aspergillus species
• Antiparasitic agents for neglected tropical diseases
• Structure-based optimization using computational modeling and AI-assisted design
• Improved safety profiles with reduced resistance potential

We anticipate advancing our lead compounds to IND-enabling studies as we secure appropriate funding and partnerships. Our approach combines traditional medicinal chemistry with cutting-edge computational methods to accelerate the discovery process.

Therapeutic Drug Monitoring ACTIVE

Our therapeutic drug monitoring service provides precise measurement of antimicrobial concentrations to optimize treatment outcomes. Currently operational for select antibiotics, we offer:

• Quantification of antimicrobial drugs in plasma and stool samples
• Monitoring capabilities for both systemic and gut-specific drug levels
• Expanding menu of antimicrobials based on clinical need

This service helps clinicians achieve therapeutic targets while minimizing toxicity and resistance development. We're actively expanding our capabilities to include more antimicrobials and sample types based on clinical demand.

Ultra-Fast, Highly-Accurate Streaming Metagenomic & Antimicrobial Resistance Profiling: BioGPU BETA

BioGPU is our Software-as-a-Service platform for rapid analysis of metagenomic sequencing data. This computational tool provides:

• Fast profiling of microbial communities from clinical and research samples
• Pathogen identification with strain-level resolution
• Detection of antimicrobial resistance genes and mutations
• User-friendly interface designed for both clinicians and researchers
• Integration capabilities with clinical decision support systems

Currently in beta testing with select partners, BioGPU represents our vision for making advanced genomic analysis accessible to improve infectious disease management. The platform can process data from various sequencing platforms and provides actionable insights within hours rather than days.

Interested in beta access? Contact us to learn more about partnership opportunities.